Interferon alpha-2a

DRUG2 trials

Sponsors

Centre Leon Berard, Hoffmann-La Roche

Conditions

Metastatic Renal Cell CarcinomaRenal Cell Cancer

Phase 2

Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma

CompletedNCT00619268

Centre Leon BerardMetastatic Renal Cell Carcinoma

Start: 2008-02-29End: 2012-02-29Target: 160Updated: 2013-02-15

Unknown Phase

Bevacizumab in Metastatic Renal Cancer

CompletedNCT02627144

Hoffmann-La RocheRenal Cell Cancer

Start: 2008-01-31End: 2014-09-30Updated: 2016-08-29

Related Papers

A group of novel <scp>VEGF</scp> splice variants as alternative therapeutic targets in renal cell carcinoma

Molecular Oncology2023-02-219 citations

Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study

Anticancer Research2019-02-015 citations

Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5

Theranostics2019-01-0151 citations

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.

2011-06-12160 citations